Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2008-12-02
2011-12-13
Kim, Yunsoo (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hormone or other secreted growth regulatory factor,...
C424S133100, C424S177100, C424S185100
Reexamination Certificate
active
08075893
ABSTRACT:
The present invention is directed to a pharmaceutical composition comprising F(ab′)2antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a pharmaceutical composition comprising F(ab′)2antibody fragments using serum or blood plasma of a mammal that has been previously immunized as a source of antibodies. The serum or blood plasma is digested with an enzyme pepsin, followed by separation and purification until the pharmaceutical composition of F(ab′)2fragments is free of albumin and complete antibodies, and substantially free of pyrogens.
REFERENCES:
patent: 4401663 (1983-08-01), Buckwalter et al.
patent: 4806346 (1989-02-01), Hum et al.
patent: 4814433 (1989-03-01), Fredrickson
patent: 4849352 (1989-07-01), Sullivan et al.
patent: 4940670 (1990-07-01), Rhodes
patent: 5328834 (1994-07-01), Ngo et al.
patent: 5443976 (1995-08-01), Carroll
patent: 5733742 (1998-03-01), Landon
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 5904922 (1999-05-01), Carroll
patent: 6270766 (2001-08-01), Feldman et al.
patent: 6333032 (2001-12-01), Skurkovich et al.
patent: 6448054 (2002-09-01), Poznansky et al.
patent: 6534059 (2003-03-01), Skurkovich et al.
patent: 6709655 (2004-03-01), de Silanes et al.
patent: 6861056 (2005-03-01), Skurkovich et al.
patent: 7232568 (2007-06-01), Skurkovich et al.
patent: 7250165 (2007-07-01), Heavner et al.
patent: 7381802 (2008-06-01), de Silanes et al.
patent: 7485303 (2009-02-01), de Silanes et al.
patent: 2001/0021380 (2001-09-01), Pluenneke
patent: 2003/0049725 (2003-03-01), Heavner et al.
patent: 2003/0180294 (2003-09-01), DeVries
patent: 2003/0215448 (2003-11-01), Skurkovich et al.
patent: 2003/0223995 (2003-12-01), Skurkovich et al.
patent: 2003/0224005 (2003-12-01), Skurkovich et al.
patent: 2003/0228310 (2003-12-01), Skurkovich et al.
patent: 2004/0062768 (2004-04-01), Skurkovich et al.
patent: 2004/0086508 (2004-05-01), Skurkovich et al.
patent: 2006/0210563 (2006-09-01), de Silanes et al.
patent: 2002237586 (2002-09-01), None
patent: 0 068 592 (1983-01-01), None
patent: 0 089 710 (1983-09-01), None
patent: 0 492 448 (1992-07-01), None
patent: 0 516 785 (1996-02-01), None
patent: 1 035 209 (2000-09-01), None
patent: 2 106 183 (1997-11-01), None
patent: WO 92/22324 (1992-12-01), None
patent: WO 00/27421 (2000-05-01), None
patent: WO 00/53786 (2000-09-01), None
patent: WO 01/58469 (2001-08-01), None
patent: WO 02/068475 (2002-09-01), None
patent: WO 2005/009464 (2005-02-01), None
Licea, A.F., et al., FAB fragments of the monoclonal antibody BCF2 are capable of neutralizing the whole venom from the scorpionCentruroides noxiushoffman,Toxicon 34:843-847, Pergamon Press Ltd. (1996).
Banks, N., “Synopses of North-American Invertebrates. IX. The Scorpions, Solpugids, and Pedipalpi,”Am. Nat. 34:421-427, Ginn & Company, Publishers (1900).
Banks, N., “The Scorpions of California,”Pomona College J. Entomol. 2:185-190, The Biological Department of Pomona College (1910).
Barona, J., et al., “Aspectos toxinológocos e immunoquímicos del veneno del escorpiónTityus pachyurusPocock de Colombia: capacidad neutralizante de antivenenos producidos en Latinoamérica, or in English: Toxicological and immunological aspects of scorpion poison (Tytius pachyurus): neutralizing capacity of antipoisons produced in Latin America,”Biomédica 24:42-49, Instituto Nacional de Salud (Mar. 2004).
Unverified English language translation of Barona, J., et al., “Toxicological and immunological aspects of scorpion poison (Tytius pachyurus): neutralizing capacity of antipoisons produced in Latin America,”Biomédica 24:42-49, Instituto Nacional de Salud (Mar. 2004).
Becerril, B., et al., “Cloning and characterization of cDNAs that code for Na+-channel-blocking toxins of the scorpionCentruroides noxiusHoffman,”Gene 128:165-171, Elsevier Science Publishers B.V. (1993).
Calderon-Aranda, E.S., et al., “Neutralizing Capacity of Murine Sera Induced by Different Antigens of Scorpion Venom,”Toxicon 31:327-337, Pergamon Press, Ltd. (1993).
Calderon-Aranda, E.S., et al., “The use of synthetic peptides can be a misleading approach to generate vaccines against scorpion toxins,”Vaccine 13:1198-1206, Elsevier Science, Ltd. (1995).
Couraud, F., et al., “Two Types of Scorpion Toxin Receptor Sites, One Related to the Activation, the Other to the Inactivation of the Action Potential Sodium Channel,”Toxicon 20:9-16, Pergamon Press, Ltd. (1982).
Curry, S.C., et al., “Envenomation by the Scorpion Centruroides Sculturatus,”J. Toxicol.-Clin. Toxicol. 21:417-449, Marcel Dekker, Inc. (1983-1984).
Dehesa-Dávila, M. and Possani, L.D., “Scorpionism and Serotherapy in Mexico,”Toxicon 32:1015-1018, Elsevier Science, Ltd. (1994).
Dehesa-Davila, M., et al., “Clinical Toxicology of Scorpion Stings,” inHandbook of Clinical Toxicology of Animal Venoms and Poisons, Meier, J. and White, J., eds., CRC Press, Boca Raton, LA, pp. 221-238 (1995).
Díaz Nájera, A., “Alacranes de la Republica Mexicana: Identificación de ejemplares capturados en 235 localidades,”Rev. Inst. Salubr. Enferm. Trop.(Méx) 24:15-30, Instituto de Salubridad y Enfermedades Tropicales (1964).
Edman, P. and Begg, G., “A Protein Sequenator,”European J. Biochem. 1:80-91, Blackwell Science, Ltd. on behalf of the Federation of European Biochemical Societies (1967).
Ewing, H.E., “The Scorpions of the Western Part of the United States, with Notes on Those Occurring in Northern Mexico,”Proc. U.S. Natl. Mus. 73:1-24, United States Government Printing Office (1928).
García, C., et al., “Isolation, Characterization and Comparison of Novel Crustacean Toxin with a Mammalian Toxin from the Venom of the ScorpionCentruroides noxiusHoffman,”Comp. Biochem. Physiol. 116B:315-322, Elsevier Science, Inc. (1997).
Gertsch, W.J., “Results of the Puritan-American Museum Expedition to Western Mexico 4. The Scorpions,”Am. Mus. Novitates, No. 1903, pp. 1-20, The American Museum of Natural History (1958).
Hoffman, C.C., “Monografias para la Entomologica Medica de Mexico, Los Scorpiones de Mexico,” in:Anales del Instituto de Biologica, Ochoterena, I., ed., Universidad Nacional Autonoma de Mexico, Mexico, pp. 243-361 (1932).
Johnson, J.D. and Allred, D.M., “Scorpions of Utah,”Great Basin Nat. 32:154-170, M.L. Bean Life Science Museum (1972).
Legros, C., et al., “Use of fusion protein constructs to generate potent immunotherapy and protection against scorpion toxins,”Vaccine 20:934-942, Elsevier Science, Ltd. (Dec. 2002).
Maraboto Martinez, J.A., et al., “Panorama Epidemiológico de las Intoxicaciones Causadas por Animales Ponzoñosos en la Población Derechohabiente del IMSS 1990-1998,” in3αReunion de Expertos en Envenenamiento por Animales Ponzoñosos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Alcapulco, Gro., México (1999).
English translation of Maraboto Martinez, J.A., et al., “Intoxications Caused by Poisonous Animals among IMSS Right-Holders, 1990-1998. An Epidemiological overview,” in3αReunión de Expertos en Envenenamiento por Animales Ponzoñosos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Alcapulco, Gro., México pp. 1-14 (1999), translated by Amador Rodriquez, J.C. (Dec. 2004).
Meeting regarding additional remarks by Dr. Marx on Aug. 4, 1887,Proc. Entomol. Soc. 1:90-94, The Entomological Society (1884-1889).
Nonner, W., “Effects ofLeiurusScorpion Venom on the “Gating” Current in Myelinated Nerve,”Adv. Cytopharmacol. 3:345-352. Raven Press (1979).
Possani, L.D., et al., &#
Alagon Cano Alejandro
García-Ubbelohde Walter J.
López De Silanes Juan
Mancilla Nava Rita Guadalupe
Paniagua-Solís Jorge F.
Instituto Bioclon, S.A. de S.V.
Kim Yunsoo
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Pharmaceutical composition of F(ab′) 2 antibody... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition of F(ab′) 2 antibody..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition of F(ab′) 2 antibody... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4260138